sparsentan (Filspari)
Jump to navigation
Jump to search
Indications
- treatment of adults with primary IgA nephropathy*
- focal segmental glomerulosclerosis
* accelerated FDA-approval
Contraindications
Dosage
Tablets: 200 mg, 400 mg
Adverse effects
* black box warning: potential hepatotoxicity & embryo-fetal toxicity
- drug adverse effects of angiotensin II receptor antagonists
- drug adverse effects of renin-angiotensin-aldosterone system inhibitors (RAAS inhibitors)
- drug adverse effects of antihypertensive agents
Mechanism of action
- non-immunosuppressive therapy
- dual endothelin angiotensin receptor antagonist
- selectively targets the endothelin A receptor & the angiotensin II subtype 1 receptor.
Notes
- restricted-distribution program (participation required)
More general terms
References
- ↑ Zoler ml FDA OKs Sparsentan for Rare Kidney Disease. Medscape. Feb 20, 2023 https://www.medscape.com/viewarticle/988482
- ↑ Monaco K FDA Approves Sparsentan as First FSGS Treatment Expanded indication supported by mixed bag of trial data. MedPage Today. April 14, 2026 https://www.medpagetoday.com/nephrology/generalnephrology/120791
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION Filspari (sparsentan) tablets, for oral use https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf